Article 21 Evidence Ladder: Class I to IV Dossier Requirements in Chile

1. Key takeaways

Article 21 of DS 825/1998 is the master provision for dossier requirements in Chile, and it builds a four-tier ladder by risk class. Class I devices must supply six basic dossier items. Class II devices add proof of a quality system (NCh-ISO 9002 or GMP). Class III devices add supporting scientific literature, the manufacturer’s effectiveness and safety studies, and quality system evidence (NCh-ISO 9001 or GMP). Class IV devices add, on top of the Class III package, representative patient population studies, studies of all inherent risks of the device, and the manufacturer’s biological studies.

GRZAN’s assessment: once this ladder is read correctly, it becomes obvious why the core of a Class III or Class IV project is not translating an instruction leaflet, but building a clinical evaluation and risk management evidence chain. The 39 categories newly brought into scope by Exempt Decree No. 25/2026 are predominantly Class III and Class IV devices, which makes the upper tiers of this ladder the operating reality for most new registrations in Chile. Planning the dossier around the ladder also gives project teams a natural progress metric: each tier closed is a tier that cannot be reopened by a deficiency letter.

2. Legal basis

• Regulation on the control of pharmaceutical products and medical devices | Decreto Supremo N° 825, de 1998 | August 21, 1999 | Article 21(a): Class I dossier requirements — (1) identification of the product, the manufacturer and the distributor (including packaging labels, package inserts, batch numbers and coding, and the working principle); (2) materials declaration (list of components and raw materials, chemical testing and biological evaluation); (3) sterilization and storage information (method, controls, shelf life, storage conditions); (4) supporting documentation for quality and manufacture, domestic or foreign; (5) performance evaluation (against Chilean official standards, or against standards approved by the Ministry of Health where none exist); (6) imported products must attach a certificate of export from the country of origin.
• Same instrument | Article 21 | Class II: all Class I items plus quality system evidence (NCh-ISO 9002, the quality assurance model for production, installation and servicing, or GMP).
• Same instrument | Article 21 | Class III: all Class I items plus supporting scientific literature, the manufacturer’s effectiveness and safety studies, and quality system evidence (NCh-ISO 9001 or GMP).
• Same instrument | Article 21 | Class IV: all Class III items plus representative patient population studies, studies of all inherent risks of the device, and the manufacturer’s biological studies.
• Same instrument | Article 20 | definitions of the four risk classes.

3. Expert insights

Insight one: the ladder is a cumulative structure, not a substitutive one.

Class II equals Class I plus the quality system; Class III equals Class I plus three new evidence blocks; Class IV equals Class III plus three further additions. No tier allows a sponsor to skip the base layer beneath it. GRZAN regularly sees Class IV sponsors concentrate all their energy on clinical studies while omitting Class I basics such as the materials declaration or the sterilization and storage information. When that happens, the dossier is not judged on its strongest elements; it is returned from the lowest tier. Checking the foundation before submission costs days, whereas a rejection at the base layer costs months of queueing time in the review pipeline. In a document review regime the base layer also sets the tone: a package whose foundation is complete signals discipline, while a package with holes at the bottom invites suspicion about every layer above it.

Insight two: Article 21 cites 1998 standard numbers, but review follows current practice.

The provision still references NCh-ISO 9002 for Class II and NCh-ISO 9001 for Classes III and IV — designations that, within the ISO system, correspond to pre-2000 editions. In practice the ISP reviews against current technical guidance, and an ISO 13485 certificate is the accepted industry approach (practical estimate). The correct preparation is therefore a dual track of statutory text plus current practice: the dossier should both explain the compliance path against the literal article and provide a current ISO 13485 certificate. Presenting only one of the two tracks invites clarification requests that stall the file while the clock of the review queue keeps running.

Insight three: among the six Class I items, items (4) and (5) are the most underestimated.

Item (4) covers documentation supporting quality and manufacture, whether domestic or foreign, and item (5) covers performance evaluation against Chilean official standards, or against standards approved by the Ministry of Health where no official standard exists. Item (5) directly mirrors the standard hierarchy of Article 111(c) of the Sanitary Code — Chilean official standards first, then international standards. This requirement determines that test reports must be mappable to Chilean standards. The mapping work described below is therefore not optional polish but a structural necessity for every class on the ladder. Sponsors sometimes delegate the six items as administrative formalities; GRZAN treats them as the first quality gate of the project, because they are the only layer common to every class.

Insight four: the Class IV study of all inherent risks is the highest level of risk management evidence.

This is not an ordinary risk analysis report; the article demands a study of the entire set of inherent risks of the device. In Class IV projects GRZAN typically breaks this obligation into four parts: an inventory of known risks, a risk evaluation matrix, a justification of the acceptability of residual risks, and a post-market surveillance plan. Structured this way, the four parts read naturally against ISO 14971 documentation, answer the article without duplicating effort, and leave a coherent trail that a reviewer can follow from hazard identification to post-market action.

4. Practical recommendations

1. Build an evidence matrix by class: use the four tiers of Article 21 as rows and the specific documents as columns, marking each cell as applicable, not applicable, prepared or pending verification.
2. Complete the six Class I items before working upward: gaps in the base layer cause the entire package to be returned.
3. Prepare quality system certificates on the dual track of statutory text plus current practice: provide the ISO 13485 certificate and explain how it corresponds to the requirements cited in the article.
4. Build an NCh standards mapping for performance evaluation: align test reports item by item with Chilean official standards, and where a standard is missing, state the basis for applying a standard approved by the Ministry of Health.
5. Organize the Class IV inherent risk study in four parts: known risk inventory, evaluation matrix, residual risk justification and post-market surveillance plan, instead of covering it with one generic risk report.

5. Verification checklist

• □ An evidence matrix for the four classes has been built against Article 21
• □ The six basic Class I dossier items are complete
• □ The quality system certificate is prepared, with its correspondence to the statutory requirements explained
• □ Performance evaluation has an established NCh standards mapping
• □ Class III scientific literature and effectiveness and safety studies are ready
• □ Class IV representative patient population studies, inherent risk studies and biological studies are ready

Regulatory information verified as of October 29, 2026.

For a product-specific feasibility assessment of Chile market entry, GRZAN’s regulatory team supports manufacturers and importers with registration dossiers, conformity documentation, standards mapping and ISP submissions. Contact info@grzanglobal.com to discuss your project.